Toripalimab Case Report in Metastatic Renal Collecting Duct Carcinoma

A 1.0 MB case report published on figshare details a single patient's response to toripalimab for metastatic collecting duct carcinoma. The report, authored by figshare admin karger and last updated in May 2026, describes a patient achieving a complete response and maintaining progression-free survival for 22 months. It is shared under a CC-BY-4.0 license.

Use Cases

• Reviewing clinical evidence for PD-1 inhibitor efficacy based on the described case of complete response.
• Studying treatment outcomes in collecting duct carcinoma based on the reported 22-month progression-free survival.
• Analyzing immunophenotype correlations with therapy response based on the CK7+/P40+ profile mentioned.

Strengths

• Case report provides specific clinical details, including drug dosage (240 mg, Q3W) and response duration (22 months PFS).
• Dataset includes source files in PDF and DOCX formats, totaling 1.0 MB.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is limited to a single case report, which may not be generalizable.

Provenance

Source

figshare

Collection Method

Case report documentation.

Freshness

Last updated 2026-05-13 05:55:36; freshness should be verified.